Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BrainBalls is a biotechnology company specializing in the creation and utilization of human brain organoids, often referred to as "mini-brains," for drug discovery and disease modeling. Founded by Dr. Alysson Muotri, a pioneer in the field of neural organoids, the company leverages induced pluripotent stem cell (iPSC) technology to grow functional, three-dimensional neural tissues that replicate human brain development and pathology. This platform allows for high-throughput screening of therapeutic compounds in a human-relevant context, aiming to overcome the limitations of traditional animal models in neuroscience. BrainBalls is particularly recognized for its research into neurodevelopmental disorders like autism and its high-profile experiments involving organoids in microgravity environments on the International Space Station. The company's technology provides a unique window into the human brain, facilitating the development of personalized treatments for complex neurological and psychiatric conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Brain Balls.